Preclinical evidence has shown that IL-6 improves ovarian cancer tumor cell survival and increases resistance to chemotherapy through the Janus kinase/signal transducer and the activator of transcription 3 (STAT3) signaling in tumor cells and the IL-6 receptor translocation in tumor endothelial cells [14]. This evidence concerns the gene STAT3 and ovarian carcinoma.